Call Options

26 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 07, 2024

BUY
$2.26 - $2.92 $2.42 Million - $3.13 Million
1,072,900 Added 646.33%
1,238,900 $3.2 Million
Q4 2023

Feb 14, 2024

BUY
$1.69 - $2.54 $159,874 - $240,284
94,600 Added 132.49%
166,000 $415,000
Q3 2023

Nov 14, 2023

SELL
$1.9 - $2.27 $69,540 - $83,082
-36,600 Reduced 33.89%
71,400 $144,000
Q2 2023

Aug 11, 2023

SELL
$2.24 - $3.06 $520,576 - $711,144
-232,400 Reduced 68.27%
108,000 $248,000
Q1 2023

May 16, 2023

BUY
$2.23 - $3.1 $458,265 - $637,050
205,500 Added 152.34%
340,400 $1.03 Million
Q4 2022

Feb 14, 2023

SELL
$1.91 - $2.85 $19,673 - $29,355
-10,300 Reduced 7.09%
134,900 $314,000
Q3 2022

Nov 14, 2022

SELL
$1.88 - $2.88 $744,856 - $1.14 Million
-396,200 Reduced 73.18%
145,200 $277,000
Q2 2022

Aug 15, 2022

BUY
$1.98 - $3.17 $186,120 - $297,980
94,000 Added 21.01%
541,400 $1.47 Million
Q1 2022

May 16, 2022

SELL
$2.42 - $3.98 $97,768 - $160,792
-40,400 Reduced 8.28%
447,400 $1.33 Million
Q4 2021

Feb 14, 2022

BUY
$3.11 - $4.61 $269,948 - $400,148
86,800 Added 21.65%
487,800 $1.9 Million
Q3 2021

Nov 15, 2021

BUY
$2.65 - $4.62 $127,465 - $222,222
48,100 Added 13.63%
401,000 $1.72 Million
Q2 2021

Aug 11, 2021

BUY
$2.5 - $3.51 $413,750 - $580,905
165,500 Added 88.31%
352,900 $1.07 Million
Q1 2021

May 17, 2021

SELL
$3.14 - $4.84 $1.1 Million - $1.7 Million
-350,500 Reduced 65.16%
187,400 $624,000
Q4 2020

Feb 16, 2021

BUY
$2.76 - $4.97 $1.07 Million - $1.92 Million
386,200 Added 254.58%
537,900 $1.91 Million
Q3 2020

Nov 16, 2020

BUY
$1.75 - $6.2 $218,750 - $775,000
125,000 Added 468.16%
151,700 $475,000
Q2 2020

Aug 14, 2020

BUY
$0.91 - $2.36 $13,195 - $34,220
14,500 Added 118.85%
26,700 $49,000
Q1 2020

May 15, 2020

SELL
$1.01 - $3.42 $64,741 - $219,222
-64,100 Reduced 84.01%
12,200 $12,000
Q4 2019

Feb 14, 2020

BUY
$0.87 - $2.89 $56,724 - $188,428
65,200 Added 587.39%
76,300 $212,000
Q2 2019

Aug 14, 2019

SELL
$1.46 - $4.44 $148,628 - $451,992
-101,800 Reduced 90.17%
11,100 $23,000
Q1 2019

May 15, 2019

BUY
$3.41 - $4.57 $325,655 - $436,435
95,500 Added 548.85%
112,900 $404,000
Q4 2018

Feb 14, 2019

SELL
$3.5 - $9.66 $52,500 - $144,900
-15,000 Reduced 46.3%
17,400 $67,000
Q3 2018

Nov 14, 2018

SELL
$7.85 - $12.35 $321,065 - $505,115
-40,900 Reduced 55.8%
32,400 $306,000
Q2 2018

Aug 14, 2018

SELL
$5.0 - $7.35 $172,000 - $252,840
-34,400 Reduced 31.94%
73,300 $535,000
Q1 2018

May 15, 2018

BUY
$4.4 - $6.05 $403,920 - $555,390
91,800 Added 577.36%
107,700 $539,000
Q4 2017

Feb 14, 2018

BUY
$4.45 - $7.7 $6,230 - $10,780
1,400 Added 9.66%
15,900 $80,000
Q3 2017

Nov 14, 2017

BUY
$3.4 - $7.0 $49,300 - $101,500
14,500
14,500 $90,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $468M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.